Literature DB >> 7727503

Difference between cancer cells and the corresponding normal tissue in view of stereoselective hydrolysis of synthetic esters.

Y Yamazaki1, Y Ogawa, A S Afify, Y Kageyama, T Okada, H Okuno, Y Yoshii, T Nose.   

Abstract

This study has aimed at taking information necessary for design of anticancer prodrugs modified with chiral acyl group, especially about the effect of chirality of the acyl group on its enzymic removal in specific cells. Thus, 13 species of chiral esters were synthesized and stereoselectivity in their enzymic hydrolysis was investigated with six cancer cell lines, solid tumors, and the corresponding normal tissues. Cultured cancer cells from rat liver, pancreas, and muscle hydrolyzed the R enantiomer of (+/-)-ethyl 2-methoxy-2-phenylacetate (3c) more preferentially than its antipode, whereas this stereoselectivity was reversed in the reaction by homogenate of the corresponding normal tissue of rat. The difference in stereoselectivity between cancer cells and normal tissue was also found in the hydrolysis of other esters including those of actual anticancer agents, p-hydroxyaniline mustard and 5-fluorouridine. The investigation was expanded to real tumor to show that the degree of stereoselectivity or the hydrolytic activity was significantly different between a human brain tumor and its surrounding normal tissue for such substrates as (+/-)-ethyl 2-phenoxypropanoate and N-trifluoroacetylphenylalaninate. The esterases of rat liver cancer cells (Anr4) and normal rat liver gave different band patterns in active staining after gel electrophoresis. The enzymes were fractionated by ion exchange column chromatography and then tested on their stereoselectivity against (+/-)-3c. Comparison of the results and electrophoretograms of the fractions suggests that esterases with different stereoselectivity are expressed in different ways by normal and cancer cells. These results show that stereoselectivity in enzymic hydrolysis of some synthetic chiral esters is different between cancer and normal cells, leading to the possibility that specific activation of ester-type anticancer prodrugs in cancer cells would be controlled by the chiral structure of the acyl group.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7727503     DOI: 10.1016/0304-4165(94)00153-o

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).

Authors:  Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-20       Impact factor: 7.446

2.  Prognostic significance of esterase gene expression in multiple myeloma.

Authors:  Romika Kumari; Muntasir Mamun Majumder; Juha Lievonen; Raija Silvennoinen; Pekka Anttila; Nina N Nupponen; Fredrik Lehmann; Caroline A Heckman
Journal:  Br J Cancer       Date:  2021-02-03       Impact factor: 7.640

3.  Experimental Conditions That Influence the Utility of 2'7'-Dichlorodihydrofluorescein Diacetate (DCFH2-DA) as a Fluorogenic Biosensor for Mitochondrial Redox Status.

Authors:  Lianne R de Haan; Megan J Reiniers; Laurens F Reeskamp; Ali Belkouz; Lei Ao; Shuqun Cheng; Baoyue Ding; Rowan F van Golen; Michal Heger
Journal:  Antioxidants (Basel)       Date:  2022-07-22

4.  Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor.

Authors:  Anujan Ramesh; Siva Kumar Natarajan; Dipika Nandi; Ashish Kulkarni
Journal:  Cell Mol Bioeng       Date:  2019-05-21       Impact factor: 2.321

5.  Identification of oxidized protein hydrolase as a potential prodrug target in prostate cancer.

Authors:  Christopher A McGoldrick; Yu-Lin Jiang; Victor Paromov; Marianne Brannon; Koyamangalath Krishnan; William L Stone
Journal:  BMC Cancer       Date:  2014-02-10       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.